# INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

> **NCT02386826** · PHASE1 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 65 (actual)

## Conditions studied

- Glioblastoma Multiforme
- Gliosarcoma
- Colorectal Cancer
- Renal Cell Carcinoma

## Interventions

- **DRUG:** INC280
- **BIOLOGICAL:** bevacizumab

## Key facts

- **NCT ID:** NCT02386826
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-22
- **Primary completion:** 2021-07-31
- **Final completion:** 2023-08-23
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2023-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02386826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02386826, "INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02386826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*